Point of Care Ultrasound Lung Artificial Intelligence (AI) Validation Data Collection Study

Pleural Effusion Clinical Trial

— AI  

Official title:

Point of Care Ultrasound Lung Artificial Intelligence (AI) Validation Data Collection Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04891705
• Other study ID #: US-Lung AI-11237
• Status: Completed
• Start date: September 11, 2021
• Est. completion date: December 14, 2023

Study information

• Verified date: November 2023
• Source: Philips Clinical & Medical Affairs Global
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is being conducted to collect image data and relevant clinical data from medical records of patients with suspicion of lung consolidation or pleural effusion. The information will be used to test the performance of Artificial Intelligence (AI) in identification of features associated with the above lung conditions.

Description:

This is a prospective, observational, multi-center, post-market clinical study. Enrollment will continue (up to a maximum of 500 adult subjects and up to 300 pediatric subjects) until diagnostic LUS exams are acquired for each of the following groups:

Approximately 500 Adult subjects targeting:

• Approximately 175 exams from patients positive for lung consolidation

• Approximately 175 exams from patients positive for pleural effusion

• Approximately 150 exams from patients negative for both conditions

Approximately 300 pediatric subjects targeting:

• Approximately 150 exams from patients positive for lung consolidation

• Approximately 150 exams from patients negative for lung consolidation

Recruitment information / eligibility

• Status: Completed
• Enrollment: 554
• Est. completion date: December 14, 2023
• Est. primary completion date: December 14, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Subjects presenting to the Emergency Department, admitted to the hospital, or seen in the outpatient setting with suspicion of pleural effusion or lung consolidation who received chest imaging to include chest X-ray or CT, or for whom chest X-ray or CT are planned.

Suspicion of pleural effusion or lung consolidation may be based upon imaging findings or presentation of symptoms including (but not limited to) dyspnea, hypoxia, tachypnea, rales, or dullness.

2. All attempts should be made for subjects to undergo scanning of 14 lung zones (adults) and 12 lung zones (pediatrics). Attempts should also be made to capture all required lung zones in adults and pediatrics. Instances where all zones cannot be captured need to be documented and reason for inability to scan them provided in EDC. See Section 8.1.3 Lung Ultrasound Exams.

3. Subject is willing to provide informed consent (or assent where age appropriate) to participate in the study. Subjects under 18 years of age require informed consent of a parent or guardian and assent as required by institutional IRB.

4. Weight of subject is greater than or equal to 10 kg.

Exclusion Criteria:

1. Subject has pathology precluding safe and pain-free ultrasound probe placement such as burn, significant soft tissue injury or surgical incisions.

2. Current imprisonment.

3. Pregnancy (self-reported)

4. Subjects with breast implants

5. Prior pleurodesis procedure.

6. History of severe lung disease and home oxygen use

7. Presence of subcutaneous air that precludes imaging

8. Body Mass Index (BMI) > 40

9. Significant scoliosis (Cobb angle = 20 degrees).

10. Pediatric subjects with chronic lung diseases other than asthma.

11. Pediatric subjects on chronic respiratory support (i.e., nasal canula, CPAP, BiPAP, or tracheostomy).

Related Conditions & MeSH terms

• Pleural Effusion

Intervention

Device:
• Lung Ultrasound Scan
Ultrasound scan of subjects in up to 14 lung zones

Locations

Country	Name	City	State
United States	University of Colorado Hospital	Aurora	Colorado
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Prisma Health Greenville Memorial Hospital	Greenville	South Carolina
United States	Yale School of Medicine	New Haven	Connecticut
United States	Arizona Emergency Medical Research Center	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Philips Clinical & Medical Affairs Global

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The study data will be used to support future performance assessments for Artificial Intelligence based algorithms as described by FDA guidance for Computer Assisted Detection and Diagnostic Devices		Discharge up to 30 days (Single visit)